Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Acute Intermittent Porphyria Drugs Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Acute Intermittent Porphyria Drugs Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 350mg
      • 1.3.3 313mg
    • 1.4 Market Segment by Application
      • 1.4.1 Global Acute Intermittent Porphyria Drugs Market Share by Application (2019-2025)
      • 1.4.2 Hospital
      • 1.4.3 Pharmacy
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Acute Intermittent Porphyria Drugs Market Size
      • 2.1.1 Global Acute Intermittent Porphyria Drugs Revenue 2014-2025
      • 2.1.2 Global Acute Intermittent Porphyria Drugs Sales 2014-2025
    • 2.2 Acute Intermittent Porphyria Drugs Growth Rate by Regions
      • 2.2.1 Global Acute Intermittent Porphyria Drugs Sales by Regions 2014-2019
      • 2.2.2 Global Acute Intermittent Porphyria Drugs Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Acute Intermittent Porphyria Drugs Sales by Manufacturers
      • 3.1.1 Acute Intermittent Porphyria Drugs Sales by Manufacturers 2014-2019
      • 3.1.2 Acute Intermittent Porphyria Drugs Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Acute Intermittent Porphyria Drugs Revenue by Manufacturers (2014-2019)
      • 3.2.2 Acute Intermittent Porphyria Drugs Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Acute Intermittent Porphyria Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.3 Acute Intermittent Porphyria Drugs Price by Manufacturers
    • 3.4 Key Manufacturers Acute Intermittent Porphyria Drugs Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Acute Intermittent Porphyria Drugs Market
    • 3.6 Key Manufacturers Acute Intermittent Porphyria Drugs Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 350mg Sales and Revenue (2014-2019)
      • 4.1.2 313mg Sales and Revenue (2014-2019)
    • 4.2 Global Acute Intermittent Porphyria Drugs Sales Market Share by Type
    • 4.3 Global Acute Intermittent Porphyria Drugs Revenue Market Share by Type
    • 4.4 Acute Intermittent Porphyria Drugs Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Acute Intermittent Porphyria Drugs Sales by Application

    6 United States

    • 6.1 United States Acute Intermittent Porphyria Drugs Breakdown Data by Company
    • 6.2 United States Acute Intermittent Porphyria Drugs Breakdown Data by Type
    • 6.3 United States Acute Intermittent Porphyria Drugs Breakdown Data by Application

    7 European Union

    • 7.1 European Union Acute Intermittent Porphyria Drugs Breakdown Data by Company
    • 7.2 European Union Acute Intermittent Porphyria Drugs Breakdown Data by Type
    • 7.3 European Union Acute Intermittent Porphyria Drugs Breakdown Data by Application

    8 China

    • 8.1 China Acute Intermittent Porphyria Drugs Breakdown Data by Company
    • 8.2 China Acute Intermittent Porphyria Drugs Breakdown Data by Type
    • 8.3 China Acute Intermittent Porphyria Drugs Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Acute Intermittent Porphyria Drugs Breakdown Data by Company
    • 9.2 Rest of World Acute Intermittent Porphyria Drugs Breakdown Data by Type
    • 9.3 Rest of World Acute Intermittent Porphyria Drugs Breakdown Data by Application
    • 9.4 Rest of World Acute Intermittent Porphyria Drugs Breakdown Data by Countries
      • 9.4.1 Rest of World Acute Intermittent Porphyria Drugs Sales by Countries
      • 9.4.2 Rest of World Acute Intermittent Porphyria Drugs Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Abbott
      • 10.1.1 Abbott Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Acute Intermittent Porphyria Drugs
      • 10.1.4 Acute Intermittent Porphyria Drugs Product Introduction
      • 10.1.5 Abbott Recent Development

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Acute Intermittent Porphyria Drugs Sales Channels
      • 11.2.2 Acute Intermittent Porphyria Drugs Distributors
    • 11.3 Acute Intermittent Porphyria Drugs Customers

    12 Market Forecast

    • 12.1 Global Acute Intermittent Porphyria Drugs Sales and Revenue Forecast 2019-2025
    • 12.2 Global Acute Intermittent Porphyria Drugs Sales Forecast by Type
    • 12.3 Global Acute Intermittent Porphyria Drugs Sales Forecast by Application
    • 12.4 Acute Intermittent Porphyria Drugs Forecast by Regions
      • 12.4.1 Global Acute Intermittent Porphyria Drugs Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Acute Intermittent Porphyria Drugs Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyrias.
      In 2019, the market size of Acute Intermittent Porphyria Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Acute Intermittent Porphyria Drugs.

      This report studies the global market size of Acute Intermittent Porphyria Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Acute Intermittent Porphyria Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Abbott
      ...

      Market Segment by Product Type
      350mg
      313mg

      Market Segment by Application
      Hospital
      Pharmacy

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Acute Intermittent Porphyria Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Acute Intermittent Porphyria Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Acute Intermittent Porphyria Drugs are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now